Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

by admin | 7月 20, 2020 | 西醫臨床科硏實證

hhhh

類型: 連結
作者: Feng-Cai Zhu et al.
出處: The Lancet
連結: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext

← The people with hidden immunity against Covid-19 Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial →